Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corp (NQ: PRTA )

15.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corp

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Prothena Corporation plc
Via Business Wire
Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate
Via Benzinga
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
Analyst Expectations for Prothena Corp's Future
Via Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Prothena Corp: Here's What You Need To Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns. 
Via Talk Markets
How To Weather These Choppy Markets
Until we get an absolute bottom in the markets, the best way to avoid experiencing a devastating permanent loss of capital is to keep away from stocks with deteriorating fundamentals and heavy insider... 
Via Talk Markets
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for... 
Via Talk Markets
What 4 Analyst Ratings Have To Say About Prothena Corp
Within the last quarter, Prothena Corp (NASDAQ:PRTA) has observed the following analyst ratings: 
Via Benzinga
Recap: Prothena Corp Q3 Earnings
Prothena Corp (NASDAQ:PRTA) reported its Q3 earnings results on Thursday, November 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
From Prothena Corporation plc
Via Business Wire
Why Prothena Shares Are Trading Lower
Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by 6.53% to $59.10 during Wednesday morning. The company announced that it has commenced an underwritten public offering of 3,000,000 of... 
Via Benzinga
Why Prothena Shares Are Nosediving During Tuesday's After-Hours Session
Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by some 8.35% to $57.95 during Tuesday's after-hours session. The company announced that it has commenced an underwritten public... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Prothena Announces Proposed Public Offering of Ordinary Shares
From Prothena Corporation plc
Via Business Wire
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
From Prothena Corporation plc
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Upgrades 
Via Benzinga
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting
From Prothena Corporation plc
Via Business Wire
Earnings Preview: Prothena Corp
Prothena Corp (NASDAQ:PRTA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Prothena Corp... 
Via Benzinga
As Small Caps Rally, These 3 Finance High-Yielders Could Have Further Upside
In the past month with the Russell 2000 index up roughly 7%, as compared to the S&P 500 index up nearly 4.8%, it is evident that small cap stocks are leading the charge in this bear market rally. The... 
Via Benzinga
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
From Prothena Corporation plc
Via GlobeNewswire
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which... 
Via FinancialNewsMedia
Netflix, Biogen And Other Big Gainers From Wednesday
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.